|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
Bio-Path Holdings Inc [BPTH]
$15.53 1.23 (7.34%)
Market Cap 40 Million
Bio-Path Holdings Inc is a United States based clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and in combination with decitabine. The other drug candidates of the company are BP1002 and BP1003.
EPS -0.89 P/E Ratio 0.00
Previous Earnings Wed, Mar 20, 2019
Pay Date --
This list of trending stocks may change throughout the trading day.